1h Free Analyst Time
Starpharma Holdings Ltd (SPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Starpharma Holdings Ltd (Starpharma) is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company's development programs include its DEP drug delivery, which is built around dendrimers and VivaGel portfolio. Its flagship product candidate, VivaGel, is a gel-based formulation for the treatment and prevention of bacterial vaginosis (BV) and it is also used as a vaginal microbicide to prevent sexually transmitted infections including HIV and genital herpes. It has license arrangements with several partners including Okamoto Industries and AstraZeneca among others. The company has research facilities in Melbourne, Australia. Starpharma is headquartered in Abbotsford, Victoria, AustraliaStarpharma Holdings Ltd Key Recent Developments
- Jun 27, 2022: Starpharma signs expanded DEP research agreement with US Biopharma Co
- Apr 27, 2022: Starpharma to present DEP at Boston ADC summit
- Feb 24, 2022: Dr Jeff Davies appointed as non-executive director
- Dec 08, 2021: Starpharma Holdings: US biopharma DEP research agreement - additional information
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Proudex Australia Pty Ltd
- ResApp Health Ltd
- Immuron Ltd
- iNova Pharmaceuticals (Australia) Pty Ltd
- Sanonda Australia Pty Ltd
- GLYDE Health Pty Ltd
- Rhinomed Ltd
- iNova Pharmaceuticals (Australia) Pty Ltd
- ResApp Health Ltd
- Immuron Ltd
- GLYDE Health Pty Ltd
- Sanonda Australia Pty Ltd
- Proudex Australia Pty Ltd
- Rhinomed Ltd